Picture of Arbutus Biopharma logo

ABUS Arbutus Biopharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Momentum

Relative Strength (%)
1m-1.91%
3m-10.43%
6m-31%
1yr-38.84%
Volume Change (%)
10d/3m+42.43%
Price vs... (%)
52w High-40.54%
50d MA+0.12%
200d MA-20.14%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-58.63%
Return on Equity-56.99%
Operating Margin-359.33%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Arbutus Biopharma EPS forecast chart

Profile Summary

Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, an oral capsid inhibitor, an oral programmed death-ligand-1 (PD-L1) inhibitor, and an oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is also having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses, including SARS-CoV-2.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
January 1st, 2018
Public Since
November 13th, 2010
No. of Shareholders
103
No. of Employees
96
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
167,695,247

ABUS Share Price Performance

Upcoming Events for ABUS

Q4 2023 Arbutus Biopharma Corp Earnings Release

Q1 2024 Arbutus Biopharma Corp Earnings Release

Arbutus Biopharma Corp Annual Shareholders Meeting

Similar to ABUS

Picture of Abcam logo

Abcam

us flag iconNASDAQ Global Select Market

Picture of Amgen logo

Amgen

us flag iconNASDAQ Global Select Market

Picture of Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Anika Therapeutics logo

Anika Therapeutics

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email